

Office of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

October 9, 2007 6:30 – 9:00 p.m.

1.	Executive Session Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreem (as provided by 33 VSA § 1998(f)(2))	6:30 - 7:00 tents
2.	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	7:00 - 7:05
3.	OVHA Pharmacy Administration Updates Specialty Pharmacy	7:05 - 7:15
4.	Medical Director Update	7:15 - 7:25
5.	Follow-up Items from Previous Meeting Biosimilar Products	7:25 - 7:30
6.	Clinical Update: Drug Reviews (Public comment prior to Board action) Brovana® Nebulization Solution (arformoterol tartrate) Reclast® Injection (zoledronic acid) Altabax® Ointment (retapamulin)	7:30 – 7:50
7.	Review of Newly-Developed/Revised Clinical Coverage Criteria (Public comment prior to Board action) Anti-Infectives: Antibiotics: Cephalosporins Anti-Infectives: Antibiotics: Quinolones Chemical Dependency: Buprenorphine	7:50 – 8:25
	 Formatting Changes Only Anti-Hypertensives: Beta-Blockers Anti-Hypertensives: Calcium Channel Blockers Coronary Vasodilators/Antianginals: Oral and Topical Gastrointestinals: Histamine-2 Receptor Antagonists Ossification Enhancing Agents Platelet Inhibitors Pulmonary: Inhaled Glucocorticoids Pulmonary: Nasal Glucocorticoids 	
8.	Drug Classes – New No new drug classes	8:25 – 8:25

8:25 - 8:35

9. RetroDUR

Suboxone[®]/Subutex[®]

10. New Drug Products Not Added to PDL	8:35 - 8:40
11. Updated New-to-Market Drug Monitoring Log	8:40 - 8:45
12. General Announcements FDA Safety Alerts Fentora®(fentanyl buccal tablet) Bisphosphonates	8:45 – 8:55
13. Adjourn	9:00